Related Experiment Video
Updated: Apr 29, 2026
Author Spotlight: Decoding DNA Repair by Extrachromosomal NHEJ Assay and HR Assays
Published on: February 2, 2024
Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples
M J Patterson1, R E Sutton2, I Forrest3
1Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Background:
Patients with malignant pleural effusions (MPEs) generally have advanced disease with poor survival and few therapeutic options. Cells within MPEs may be used to stratify patients for targeted therapy. Targeted therapy with poly(ADP ribose) polymerase inhibitors (PARPi) depends on identifying homologous recombination DNA repair (HRR)-defective cancer cells. We aimed to determine the feasibility of assaying HRR status in MPE cells.
Methods:
A total of 15 MPE samples were collected from consenting patients with non-small-cell lung cancer (NSCLC), mesothelioma and ovarian and breast cancer. Primary cultures were confirmed as epithelial by pancytokeratin, and HRR status was determined by the detection of γH2AX and RAD51 foci following a 24-h exposure to rucaparib, by immunofluorescence microscopy. Massively parallel next-generation sequencing of DNA repair genes was performed on cultured MPE cells.
Results:
From 15 MPE samples, 13 cultures were successfully established, with HRR function successfully determined in 12 cultures. Four samples - three NSCLC and one mesothelioma - were HRR defective and eight samples - one NSCLC, one mesothelioma, one sarcomatoid, one breast and four ovarian cancers - were HRR functional. No mutations in DNA repair genes were associated with HRR status, but there was probable loss of heterozygosity of FANCG, RPA1 and PARP1.
Conclusions:
HRR function can be successfully detected in MPE cells demonstrating the potential to stratify patients for targeted therapy with PARPi.
Insights
Assessing homologous recombination repair (HRR) status in malignant pleural effusion (MPE) cells is feasible. This finding supports patient stratification for targeted poly(ADP ribose) polymerase inhibitor (PARPi) therapy in advanced cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Malignant pleural effusions (MPEs) are common in advanced cancers with limited treatment options.
- MPE cells can potentially guide targeted therapy selection.
- Poly(ADP ribose) polymerase inhibitors (PARPi) efficacy relies on identifying homologous recombination DNA repair (HRR)-defective cancer cells.
Purpose of the Study:
- To evaluate the feasibility of determining HRR status in MPE cells.
- To explore MPE cell utility for patient stratification in targeted cancer therapy.
Main Methods:
- Collected 15 MPE samples from patients with non-small-cell lung cancer, mesothelioma, ovarian, and breast cancers.
- Established primary MPE cell cultures and confirmed epithelial origin.
- Assessed HRR status via immunofluorescence for γH2AX and RAD51 foci after rucaparib exposure.
- Performed next-generation sequencing of DNA repair genes on cultured MPE cells.
Main Results:
- Successfully established 13 of 15 MPE cultures and determined HRR status in 12.
- Identified 4 HRR-defective samples (3 NSCLC, 1 mesothelioma) and 8 HRR-functional samples.
- Observed probable loss of heterozygosity in FANCG, RPA1, and PARP1, but no direct mutation association with HRR status.
Conclusions:
- HRR function can be reliably detected in MPE cells.
- This assay provides a method to stratify patients for PARPi therapy.
- MPE analysis holds promise for personalized cancer treatment strategies.
Related Concept Videos
02:31Homologous Recombination
02:31Homologous Recombination
02:04Fixing Double-strand Breaks
01:54Base Excision Repair
The first step of...
01:08Nucleotide Excision Repair
01:38Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...